Overexpression of Adiponectin Receptors in Opium Users With and Without Cancer

Overexpression of Adiponectin Receptors in Opium Users With and Without Cancer Publisher

Firouzabadi N^{1, 2, 3} ; Haghnegahdar M¹ ; Khalvati B⁴ ; Dehshahri A⁵ ; Bahramali E⁶

Show Affiliations

1. Department of Pharmacology & Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
2. Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3. Non-Communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
4. Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
5. Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
6. Digestive Disease Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Clinical Pharmacology: Advances and Applications Published:2020

Abstract

Aim: Opium addiction is a serious public health concern in the Middle East countries causing various illnesses. Opium use is associated with an increased risk of several cancers; however, the underlying mechanisms are not yet fully elucidated. Altered levels of adiponectin and its related main receptors, Adiponectin receptor 1 and 2 (AdipoR1 and AdipoR2) have been associated with several malignancies. Opium users are at risk of various cancers. All together let us to the hypothesis that probable overexpression of AdipoRs in opium users might be linked to the occurrence of cancer in this population. Methods: One hundred opium users along with 100 healthy non-opium users were enrolled in the study. Opium users were followed up for 5 years (2014–2019) to evaluate the occurrence of malignancies. AdipoR1 and AdipoR2 expressions were measured using a flow cytometry method. Results: Expression of AdipoR1 and AdipoR2 was significantly higher in opium users compared with the healthy control group (P=0.0001 and 0.0001, respectively). Eight opium users developed cancer during the follow-up period. Subjects abusing opium developed cancer by 8.6 folds comparing to non-opium users (P=0.034; OR=8.6; 95% CI (1.06– 70.1)). Expression of these two receptors was significantly higher in opium users developing cancer compared with cancer-free opium (P=0.001). Conclusion: Considering the significant overexpression of AdipoR1 and AdipoR2 in opium users and in opium users who developed malignancies and the association between upregulation of these receptors in most cancers affecting opium users and assessment of AdipoRs may serve as an early detection tool of cancer in this population. © 2020 Firouzabadi et al.

Related Docs

View other Related Docs

1. Opium Use and Subsequent Incidence of Cancer: Results From the Golestan Cohort Study, The Lancet Global Health (2020)

2. The Iranian Study of Opium and Cancer (Iropican): Rationale, Design, and Initial Findings, Archives of Iranian Medicine (2021)

3. Mortality From Respiratory Diseases Associated With Opium Use: A Population-Based Cohort Study, Thorax (2017)

4. Opium Use, Cigarette Smoking, and Alcohol Consumption in Relation to Pancreatic Cancer, Medicine (United States) (2016)

5. The Carcinogenicity of Opium Consumption: A Systematic Review and Meta-Analysis, European Journal of Epidemiology (2023)

6. Opium Use and Risk of Pancreatic Cancer: A Prospective Cohort Study, Cancer Epidemiology Biomarkers and Prevention (2018)

7. Opiate and Tobacco Use and Exposure to Carcinogens and Toxicants in the Golestan Cohort Study, Cancer Epidemiology Biomarkers and Prevention (2020)

8. Fifty Years of Research and One Conclusion: Opium Causes Cancer, Archives of Iranian Medicine (2020)

Experts (# of related papers)

View all Related Experts

Reza Malekzadeh (24)

Hossein Poustchi (20)

Style	Citing Format
MLA	Firouzabadi N, et al.. "Overexpression of Adiponectin Receptors in Opium Users With and Without Cancer." Clinical Pharmacology: Advances and Applications, vol. 12, no. , 2020, pp. 59-65.
APA	Firouzabadi N, Haghnegahdar M, Khalvati B, Dehshahri A, Bahramali E (2020). Overexpression of Adiponectin Receptors in Opium Users With and Without Cancer. Clinical Pharmacology: Advances and Applications, 12(), 59-65.
Chicago	Firouzabadi N, Haghnegahdar M, Khalvati B, Dehshahri A, Bahramali E. "Overexpression of Adiponectin Receptors in Opium Users With and Without Cancer." Clinical Pharmacology: Advances and Applications 12, no. (2020): 59-65.
Harvard	Firouzabadi N et al. (2020) 'Overexpression of Adiponectin Receptors in Opium Users With and Without Cancer', Clinical Pharmacology: Advances and Applications, 12(), pp. 59-65.
Vancouver	Firouzabadi N, Haghnegahdar M, Khalvati B, Dehshahri A, Bahramali E. Overexpression of Adiponectin Receptors in Opium Users With and Without Cancer. Clinical Pharmacology: Advances and Applications. 2020;12():59-65.
BibTex	@article{ author = {Firouzabadi N and Haghnegahdar M and Khalvati B and Dehshahri A and Bahramali E}, title = {Overexpression of Adiponectin Receptors in Opium Users With and Without Cancer}, journal = {Clinical Pharmacology: Advances and Applications}, volume = {12}, number = {}, pages = {59-65}, year = {2020} }
RIS	TY - JOUR AU - Firouzabadi N AU - Haghnegahdar M AU - Khalvati B AU - Dehshahri A AU - Bahramali E TI - Overexpression of Adiponectin Receptors in Opium Users With and Without Cancer JO - Clinical Pharmacology: Advances and Applications VL - 12 IS - SP - 59 EP - 65 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract